A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches (Q34003508)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

multicenter clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

botulinum toxin type A

1 reference

based on heuristic

inferred from title

author name string

M Relja

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

A C Poole

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

J Schoenen

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

J Pascual

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

X Lei

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

C Thompson

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

European BoNTA Headache Study Group

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

11 April 2007

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

492-503

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Topiramate in migraine prevention: results of a large controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Prevalence and burden of migraine in the United States: data from the American Migraine Study II.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Migraine in the United States: epidemiology and patterns of health care use.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Migraine: preventive treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

The burden of migraine in Spain: beyond direct costs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Burden of migraine in the United States: disability and economic costs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Migraine, quality of life, and depression: a population-based case-control study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Migraine headache disability and health-related quality-of-life: a population-based case-control study from England.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Migraine preventive medication reduces resource utilization

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

The economic burden of migraine to society

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Burden of migraine in Brazil: estimate of cost of migraine to the public health system and an analytical study of the cost-effectiveness of a stratified model of care

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Economic impact of migraine and other episodic headaches in France: data from the GRIM2000 study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Migraine--current understanding and treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Topiramate for migraine prevention: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Evidence for antinociceptive activity of botulinum toxin type A in pain management

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Subcutaneous administration of botulinum toxin A reduces formalin-induced pain

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Focused review: Botulinum toxin type A therapy in chronic pain disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: from bench to bedside

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Botulinum toxin A in the prophylactic treatment of migraine--a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Procedures for administering botulinum toxin type A for migraine and tension-type headache

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Efficacy of gabapentin in migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Placebo effect and clinical trials in migraine therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Placebo response in clinical randomized trials of analgesics in migraine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Placebo effects in oral triptan trials: the scientific and ethical rationale for continued use of placebo controls

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Neurobiological mechanisms of the placebo effect.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Repeatability of autonomic responses to pain anticipation and pain stimulation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Mechanisms of the placebo response and their impact on clinical trials and clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Placebo effects mediated by endogenous opioid activity on mu-opioid receptors.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Belief or Need? Accounting for individual variations in the neurochemistry of the placebo effect

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Ethical aspects of placebo in migraine research

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-2982.2007.01315.X

21 January 2018

Identifiers

10.1111/J.1468-2982.2007.01315.X

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34003508&oldid=1537447396"